Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MyoCell II
- Development stage
- Discontinued
- Lead developer
- Bioheart
- Modality
- Cell Therapies, Gene Therapies
- Administration
- Intramyocardial
01
Overview
MyoCell II is a second-generation autologous cell therapy developed by Bioheart (now U.S. Stem Cell) for the treatment of congestive heart failure and chronic myocardial ischemia. The therapy consists of skeletal myoblasts harvested from the patient's own muscle tissue, which are then expanded ex vivo and genetically modified using a non-viral plasmid to overexpress Stromal Cell-Derived Factor-1 (SDF-1). Once injected intramyocardially, the myoblasts provide structural support to the damaged heart wall, while the secreted SDF-1 acts as a potent chemoattractant for endogenous stem and progenitor cells. This dual mechanism is intended to promote myocardial regeneration, enhance angiogenesis, and improve overall cardiac function in patients with heart failure following a myocardial infarction.
- Brand names
- MyoCell II
- Other names
- MyoCell SDF-1Autologous skeletal myoblasts expressing SDF-1SDF-1 modified myoblastsSDF1 modified myoblastsSDF 1 modified myoblasts
02
Targets
CXCR4 (C-X-C motif chemokine receptor 4)CXCR7 (CXC chemokine receptor 7)
Beyond the preview
Go deeper on MyoCell II.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MyoCell II.